The final CMS reimbursement bundle strengthens the case for home

Beginning in 2011, Centers for Medicare and Medicaid Services (CMS) provided an End-Stage Renal Disease (ESRD) Prospective Payment System that does not rely on separate payment rates based on modality. Peritoneal Dialysis (PD), typically utilizes fewer facility resources, and CMS has stated that this rate change is a clear incentive for facilities to make home therapies available to more patients.1

What is included


  • Medications: In addition to all current composite rate services, CMS will now include all ESRD intravenous Part B medications and their oral equivalents within the bundled payment.
  • Labs: All ESRD-related labs ordered by the facility or nephrologist will now be included within the bundled payment. All non-ESRD-related labs will remain separately billable.1 CMS will post a detailed list of ESRD and non-ESRD labs; visit their site for more information*

*The following are online resources from professional associations, government entities, and consumer organizations that provide more information. Baxter Healthcare Corporation does not review or control the content of any non-Baxter site. Baxter Healthcare Corporation does not endorse and is not responsible for the accuracy, content, practices or standards of any non-Baxter sources.

 

1 End-Stage Renal Disease Prospective Payment System, 42 CFR Part 410, 413 and 414, [CMS-1418-P]; Center for Medicare and Medicaid Services.

 CMS has provided a clear incentive for facilities to make home therapies available to more patients.